OncoMatch/Clinical Trials/NCT04147078

Personalized DC Vaccine for Postoperative Cancer

Is NCT04147078 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DC vaccine subcutaneous administration for gastric cancer.

Phase 1RecruitingSichuan UniversityNCT04147078Data as of May 2026

Treatment: DC vaccine subcutaneous administration — The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Carcinoma

Colorectal Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate organ functions

Kidney function

adequate organ functions

Liver function

adequate organ functions

Adequate organ functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify